{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,4]],"date-time":"2025-09-04T14:14:47Z","timestamp":1756995287242,"version":"3.37.3"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T00:00:00Z","timestamp":1507680000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["NIH- NHLBI-5 UM1 HL087366-10","1R01HL132448-01","R01 HL033610-29","R01 HL056921-19"],"award-info":[{"award-number":["NIH- NHLBI-5 UM1 HL087366-10","1R01HL132448-01","R01 HL033610-29","R01 HL056921-19"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NCATS-University of Florida Clinical and Translational Science","award":["UL1TR001427"],"award-info":[{"award-number":["UL1TR001427"]}]},{"name":"PCORnet-OneFlorida","award":["CDRN-1501-26692"],"award-info":[{"award-number":["CDRN-1501-26692"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cardiovasc Toxicol"],"published-print":{"date-parts":[[2018,4]]},"DOI":"10.1007\/s12012-017-9429-8","type":"journal-article","created":{"date-parts":[[2017,10,11]],"date-time":"2017-10-11T14:57:05Z","timestamp":1507733825000},"page":"184-191","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Unanticipated Cardiotoxicity Associated with Targeted Anticancer Therapy in Patients with Hematologic Malignancies Patients: Natural History and Risk Factors"],"prefix":"10.1007","volume":"18","author":[{"given":"Chintan","family":"Shah","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yan","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anita","family":"Szady","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qian","family":"Sun","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carl J.","family":"Pepine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Taimour","family":"Langaee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra R.","family":"Lucas","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9330-7500","authenticated-orcid":false,"given":"Jan S.","family":"Moreb","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,10,11]]},"reference":[{"key":"9429_CR1","first-page":"7","volume":"66","author":"RL Siegel","year":"2016","unstructured":"Siegel, R. L., Miller, K. D., & Jemal, A. (2016). Cancer statistics. CA: A Cancer Journal for Clinicians, 66, 7\u201330.","journal-title":"CA: A Cancer Journal for Clinicians"},{"key":"9429_CR2","doi-asserted-by":"publisher","first-page":"675","DOI":"10.3892\/mco.2016.800","volume":"4","author":"Z Chen","year":"2016","unstructured":"Chen, Z., & Ai, D. (2016). Cardiotoxicity associated with targeted cancer therapies. Molecular and Clinical Oncology, 4, 675\u2013681.","journal-title":"Molecular and Clinical Oncology"},{"key":"9429_CR3","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1007\/s11906-010-0146-y","volume":"12","author":"CA Geisberg","year":"2010","unstructured":"Geisberg, C. A., & Sawyer, D. B. (2010). Mechanisms of anthracycline cardiotoxicity and strategies to decrease cardiac damage. Current Hypertension Reports, 12, 404\u2013410.","journal-title":"Current Hypertension Reports"},{"key":"9429_CR4","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1111\/imj.13305","volume":"47","author":"AA Khan","year":"2017","unstructured":"Khan, A. A., Ashraf, A., Singh, R., Rahim, A., Rostom, W., Hussain, M., et al. (2017). Incidence, time of occurrence and response to heart failure therapy in patients with anthracycline cardiotoxicity. Internal Medicine Journal, 47, 104\u2013109.","journal-title":"Internal Medicine Journal"},{"key":"9429_CR5","doi-asserted-by":"publisher","first-page":"1031","DOI":"10.1056\/NEJM200104053441401","volume":"344","author":"BJ Druker","year":"2001","unstructured":"Druker, B. J., Talpaz, M., Resta, D. J., Peng, B., Buchdunger, E., Ford, J. M., et al. (2001). Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. New England Journal of Medicine, 344, 1031\u20131037.","journal-title":"New England Journal of Medicine"},{"key":"9429_CR6","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1093\/jnci\/djp440","volume":"102","author":"A Albini","year":"2010","unstructured":"Albini, A., Pennesi, G., Donatelli, F., Cammarota, R., De Flora, S., & Noonan, D. M. (2010). Cardiotoxicity of anticancer drugs: The need for cardio-oncology and cardio-oncological prevention. Journal of the National Cancer Institute, 102, 14\u201325.","journal-title":"Journal of the National Cancer Institute"},{"key":"9429_CR7","doi-asserted-by":"publisher","first-page":"84","DOI":"10.1161\/CIRCULATIONAHA.108.776831","volume":"118","author":"MH Chen","year":"2008","unstructured":"Chen, M. H., Kerkel\u00e4, R., & Force, T. (2008). Mechanisms of cardiac dysfunction associated with tyrosine kinase inhibitor cancer therapeutics. Circulation, 118, 84\u201395.","journal-title":"Circulation"},{"key":"9429_CR8","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1200\/JCO.2002.20.5.1215","volume":"20","author":"A Seidman","year":"2002","unstructured":"Seidman, A., Hudis, C., Pierri, M. K., Shak, S., Paton, V., Ashby, M., et al. (2002). Cardiac dysfunction in the trastuzumab clinical trials experience. Journal of Clinical Oncology, 20, 1215\u20131221.","journal-title":"Journal of Clinical Oncology"},{"issue":"Suppl 7","key":"9429_CR9","doi-asserted-by":"publisher","first-page":"vii155","DOI":"10.1093\/annonc\/mds293","volume":"23","author":"G Curigliano","year":"2012","unstructured":"Curigliano, G., Cardinale, D., Suter, T., Plataniotis, G., de Azambuja, E., Sandri, M. T., et al. (2012). ESMO Guidelines Working Group. Cardiovascular toxicity induced by chemotherapy, targeted agents and radiotherapy: ESMO clinical practice guidelines. Annals of Oncology, 23(Suppl 7), vii155\u2013vii166.","journal-title":"Annals of Oncology"},{"key":"9429_CR10","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.repc.2012.11.002","volume":"32","author":"R Ad\u00e3o","year":"2013","unstructured":"Ad\u00e3o, R., de Keulenaer, G., Leite-Moreira, A., & Br\u00e1s-Silva, C. (2013). Cardiotoxicity associated with cancer therapy: Pathophysiology and prevention strategies. Revista Portuguesa de Cardiologia, 32, 395\u2013409.","journal-title":"Revista Portuguesa de Cardiologia"},{"key":"9429_CR11","doi-asserted-by":"publisher","first-page":"e87671","DOI":"10.1371\/journal.pone.0087671","volume":"9","author":"Y Xiao","year":"2014","unstructured":"Xiao, Y., Yin, J., Wei, J., & Shang, Z. (2014). Incidence and risk of cardiotoxicity associated with bortezomib in the treatment of cancer: A systematic review and meta-analysis. PLoS ONE, 9, e87671.","journal-title":"PLoS ONE"},{"key":"9429_CR12","doi-asserted-by":"publisher","first-page":"899","DOI":"10.1182\/blood-2014-02-556308","volume":"124","author":"N Lendvai","year":"2014","unstructured":"Lendvai, N., Hilden, P., Devlin, S., Landau, H., Hassoun, H., Lesokhin, A. M., et al. (2014). A phase 2 single-center study of carfilzomib 56\u00a0mg\/m2 with or without low-dose dexamethasone in relapsed multiple myeloma. Blood, 124, 899\u2013906.","journal-title":"Blood"},{"key":"9429_CR13","doi-asserted-by":"publisher","first-page":"298","DOI":"10.1007\/s12094-008-0201-1","volume":"10","author":"JM Cervera Grau","year":"2008","unstructured":"Cervera Grau, J. M., Esquerdo Galiana, G., Belso Candela, A., Llorca Ferr\u00e1ndiz, C., Ju\u00e1rez Marroqu\u00ed, A., & Maci\u00e1, Escalante. S. (2008). Complete atrioventricular block induced by rituximab in monotherapy in an aged patient with non-Hodgkin\u2019s diffuse large B-cell lymphoma. Clinical and Translational Oncology, 10, 298\u2013299.","journal-title":"Clinical and Translational Oncology"},{"key":"9429_CR14","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1007\/s12032-008-9062-2","volume":"25","author":"S Kilickap","year":"2008","unstructured":"Kilickap, S., Yavuz, B., Aksoy, S., Sahiner, L., Dincer, M., Harputluoglu, H., et al. (2008). Addition of rituximab to chop does not increase the risk of cardiotoxicity in patients with non-Hodgkin\u2019s lymphoma. Medical Oncology, 25, 437\u2013442.","journal-title":"Medical Oncology"},{"key":"9429_CR15","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1200\/JCO.2000.18.2.317","volume":"18","author":"JM Foran","year":"2000","unstructured":"Foran, J. M., Rohatiner, A. Z., Cunningham, D., Popescu, R. A., Solal-Celigny, P., Ghielmini, M., et al. (2000). European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. Journal of Clinical Oncology, 18, 317\u2013324.","journal-title":"Journal of Clinical Oncology"},{"key":"9429_CR16","doi-asserted-by":"crossref","first-page":"32519","DOI":"10.18632\/oncotarget.8685","volume":"7","author":"K Xue","year":"2016","unstructured":"Xue, K., Gu, J. J., Zhang, Q., Liu, X., Wang, J., Li, X. Q., et al. (2016). Cardiotoxicity as indicated by LVEF and troponin T sensitivity following two anthracycline-based regimens in lymphoma: Results from a randomized prospective clinical trial. Oncotarget, 7, 32519\u201332531.","journal-title":"Oncotarget"},{"key":"9429_CR17","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos, M. A., Moreau, P., Palumbo, A., Joshua, D., Pour, L., H\u00e1jek, R., et al. (2016). Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): A randomised, phase 3, open-label, multicentre study. The Lancet Oncology, 17, 27\u201338.","journal-title":"The Lancet Oncology"},{"key":"9429_CR18","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1111\/ejh.12677","volume":"97","author":"S Danhof","year":"2016","unstructured":"Danhof, S., Schreder, M., Rasche, L., Strifler, S., Einsele, H., & Knop, S. (2016). \u2018Real-life\u2019 experience of preapproval carfilzomib-based therapy in myeloma\u2014Analysis of cardiac toxicity and predisposing factors. European Journal of Haematology, 97, 25\u201332.","journal-title":"European Journal of Haematology"},{"key":"9429_CR19","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.cardfail.2014.11.008","volume":"21","author":"EW Grandin","year":"2015","unstructured":"Grandin, E. W., Ky, B., Cornell, R. F., Carver, J., & Lenihan, D. J. (2015). Patterns of cardiac toxicity associated with irreversible proteasome inhibition in the treatment of multiple myeloma. Journal of Cardiac Failure, 21, 138\u2013144.","journal-title":"Journal of Cardiac Failure"},{"key":"9429_CR20","doi-asserted-by":"publisher","first-page":"E15","DOI":"10.1002\/ajh.24599","volume":"92","author":"JC Reneau","year":"2017","unstructured":"Reneau, J. C., Asante, D., van Houten, H., Sangaralingham, L. R., Buadi, F. K., Lerman, A., et al. (2017). Cardiotoxicity risk with bortezomib versus lenalidomide for treatment of multiple myeloma: A propensity matched study of 1790 patients. American Journal of Hematology, 92, E15\u2013E17.","journal-title":"American Journal of Hematology"},{"key":"9429_CR21","doi-asserted-by":"publisher","first-page":"e384","DOI":"10.1038\/bcj.2015.112","volume":"6","author":"A Rosenthal","year":"2016","unstructured":"Rosenthal, A., Luthi, J., Belohlavek, M., Kort\u00fcm, K. M., Mookadam, F., Mayo, A., et al. (2016). Carfilzomib and the cardiorenal system in myeloma: An endothelial effect? Blood Cancer Journal, 6, e384.","journal-title":"Blood Cancer Journal"},{"key":"9429_CR22","doi-asserted-by":"publisher","first-page":"346","DOI":"10.4103\/0973-1482.87003","volume":"7","author":"P Arunprasath","year":"2011","unstructured":"Arunprasath, P., Gobu, P., Dubashi, B., Satheesh, S., & Balachander, J. (2011). Rituximab induced myocardial infarction: A fatal drug reaction. Journal of Cancer Research and Therapeutics, 7, 346\u2013348.","journal-title":"Journal of Cancer Research and Therapeutics"},{"key":"9429_CR23","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1002\/ajh.20303","volume":"78","author":"Y Arai","year":"2005","unstructured":"Arai, Y., Tadokoro, J., & Mitani, K. (2005). Ventricular tachycardia associated with infusion of rituximab in mantle cell lymphoma. American Journal of Hematology, 78, 317\u2013318.","journal-title":"American Journal of Hematology"},{"key":"9429_CR24","doi-asserted-by":"publisher","DOI":"10.1136\/bcr-2014-208203","author":"KH Ng","year":"2015","unstructured":"Ng, K. H., Dearden, C., & Gruber, P. (2015). Rituximab-induced Takotsubo syndrome: More cardiotoxic than it appears? BMJ Case Reports. doi:\n                    10.1136\/bcr-2014-208203\n                    \n                  .","journal-title":"BMJ Case Reports"},{"key":"9429_CR25","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","volume":"346","author":"B Coiffier","year":"2002","unstructured":"Coiffier, B., Lepage, E., Briere, J., Herbrecht, R., Tilly, H., Bouabdallah, R., et al. (2002). CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. New England Journal of Medicine, 346, 235\u2013242.","journal-title":"New England Journal of Medicine"},{"key":"9429_CR26","doi-asserted-by":"publisher","first-page":"908","DOI":"10.1038\/nm1446","volume":"12","author":"R Kerkel\u00e4","year":"2006","unstructured":"Kerkel\u00e4, R., Grazette, L., Yacobi, R., Iliescu, C., Patten, R., Beahm, C., et al. (2006). Cardiotoxicity of the cancer therapeutic agent imatinib mesylate. Nature Medicine, 12, 908\u2013916.","journal-title":"Nature Medicine"},{"key":"9429_CR27","doi-asserted-by":"publisher","first-page":"2231","DOI":"10.1016\/j.jacc.2009.02.050","volume":"53","author":"ET Yeh","year":"2009","unstructured":"Yeh, E. T., & Bickford, C. L. (2009). Cardiovascular complications of cancer therapy: Incidence, pathogenesis, diagnosis, and management. Journal of the American College of Cardiology, 53, 2231\u20132247.","journal-title":"Journal of the American College of Cardiology"},{"key":"9429_CR28","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1016\/S1470-2045(15)00559-8","volume":"17","author":"M Trn\u011bn\u00fd","year":"2016","unstructured":"Trn\u011bn\u00fd, M., Lamy, T., Walewski, J., Belada, D., Mayer, J., Radford, J., et al. (2016). Lenalidomide versus investigator\u2019s choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): A phase 2, randomised, multicentre trial. The Lancet Oncology, 17, 319\u2013331.","journal-title":"The Lancet Oncology"},{"key":"9429_CR29","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1007\/s11899-017-0369-y","volume":"12","author":"TK Sethi","year":"2017","unstructured":"Sethi, T. K., Basdag, B., Bhatia, N., Moslehi, J., & Reddy, N. M. (2017). Beyond anthracyclines: Preemptive management of cardiovascular toxicity in the era of targeted agents for hematologic malignancies. Current Hematologic Malignancy Reports, 12, 257\u2013267.","journal-title":"Current Hematologic Malignancy Reports"},{"key":"9429_CR30","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/s12012-016-9378-7","volume":"17","author":"BB Hasinoff","year":"2017","unstructured":"Hasinoff, B. B., Patel, D., & Wu, X. (2017). Molecular mechanisms of the cardiotoxicity of the proteasomal-targeted drugs bortezomib and carfilzomib. Cardiovascular Toxicology, 17, 237\u2013250.","journal-title":"Cardiovascular Toxicology"},{"key":"9429_CR31","doi-asserted-by":"publisher","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","volume":"5","author":"AA Khorana","year":"2007","unstructured":"Khorana, A. A., Francis, C. W., Culakova, E., Kuderer, N. M., & Lyman, G. H. (2007). Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy. Journal of Thrombosis and Haemostasis, 5, 632\u2013634.","journal-title":"Journal of Thrombosis and Haemostasis"},{"key":"9429_CR32","doi-asserted-by":"publisher","first-page":"2108","DOI":"10.1172\/JCI24682","volume":"115","author":"I Shiojima","year":"2005","unstructured":"Shiojima, I., Sato, K., Izumiya, Y., Schiekofer, S., Ito, M., Liao, R., et al. (2005). Disruption of coordinated cardiac hypertrophy and angiogenesis contributes to the transition to heart failure. The Journal of Clinical Investigation, 115, 2108\u20132118.","journal-title":"The Journal of Clinical Investigation"},{"key":"9429_CR33","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1056\/NEJMoa1505517","volume":"374","author":"JS Ware","year":"2016","unstructured":"Ware, J. S., Li, J., Mazaika, E., Yasso, C. M., DeSouza, T., Cappola, T. P., et al. (2016). Shared genetic predisposition in peripartum and dilated cardiomyopathies. New England Journal of Medicine, 374, 233\u2013241.","journal-title":"New England Journal of Medicine"},{"key":"9429_CR34","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.1016\/j.bbmt.2016.02.017","volume":"22","author":"KJ Leger","year":"2016","unstructured":"Leger, K. J., Cushing-Haugen, K., Hansen, J. A., Fan, W., Leisenring, W. M., Martin, P. J., et al. (2016). Clinical and genetic determinants of cardiomyopathy risk among hematopoietic cell transplantation survivors. Biology of Blood and Marrow Transplantation, 22, 1094\u20131101.","journal-title":"Biology of Blood and Marrow Transplantation"},{"key":"9429_CR35","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.yjmcc.2007.10.015","volume":"44","author":"HM Nef","year":"2008","unstructured":"Nef, H. M., M\u00f6llmann, H., Troidl, C., Kostin, S., B\u00f6ttger, T., Voss, S., et al. (2008). Expression profiling of cardiac genes in Tako-Tsubo cardiomyopathy: Insight into a new cardiac entity. Journal of Molecular and Cellular Cardiology, 44, 395\u2013404.","journal-title":"Journal of Molecular and Cellular Cardiology"},{"key":"9429_CR36","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1253\/circj.CJ-09-0465","volume":"73","author":"M Asakura","year":"2009","unstructured":"Asakura, M., & Kitakaze, M. (2009). Global gene expression profiling in the failing myocardium. Circulation Journal, 73, 1568\u20131576.","journal-title":"Circulation Journal"}],"container-title":["Cardiovascular Toxicology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s12012-017-9429-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-017-9429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s12012-017-9429-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T17:52:19Z","timestamp":1589737939000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s12012-017-9429-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,10,11]]},"references-count":36,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2018,4]]}},"alternative-id":["9429"],"URL":"https:\/\/doi.org\/10.1007\/s12012-017-9429-8","relation":{},"ISSN":["1530-7905","1559-0259"],"issn-type":[{"type":"print","value":"1530-7905"},{"type":"electronic","value":"1559-0259"}],"subject":[],"published":{"date-parts":[[2017,10,11]]},"assertion":[{"value":"11 October 2017","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}}]}}